OptimizeRx (OPRX) 10-K 10 Mar 23 2022 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2022	Feb. 28, 2023	Jun. 30, 2022
Document Information Line Items
Entity Registrant Name	OptimizeRx Corp
Trading Symbol	OPRX
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		17,100,097
Entity Public Float			$ 486,888,119
Amendment Flag	false
Entity Central Index Key	0001448431
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	false
Document Annual Report	true
Document Transition Report	false
Entity File Number	001-38543
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	26-1265381
Entity Address, Address Line One	400 Water Street
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	Rochester
Entity Address, State or Province	MI
Entity Address, Postal Zip Code	48307
City Area Code	248
Local Phone Number	651-6568
Title of 12(b) Security	Common Stock, par value $0.001
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Auditor Name	UHY LLP
Auditor Location	Sterling Heights, Michigan
Auditor Firm ID	1195

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current Assets
Cash and cash equivalents	$ 18,208,685	$ 84,681,770
Short-term investments	55,931,821
Accounts receivable, net	22,155,301	24,800,585
Prepaid expenses and other	2,280,828	5,630,655
Total Current Assets	98,576,635	115,113,010
Property and equipment, net	137,448	143,818
Other Assets
Goodwill	22,673,820	14,740,031
Technology assets, net	7,702,895	4,589,126
Patent rights, net	1,940,178	2,155,026
Right of use assets, net	235,320	328,820
Other intangible assets, net	3,379,838	3,902,502
Security deposits and other assets	5,051	12,859
Total Other Assets	35,937,102	25,728,364
TOTAL ASSETS	134,651,185	140,985,192
Current Liabilities
Accounts payable – trade	1,549,979	606,808
Accrued expenses	2,601,246	2,902,836
Revenue share payable	3,990,440	4,378,216
Current portion of lease liabilities	89,902	90,982
Deferred revenue	164,309	1,389,907
Total Current Liabilities	8,395,876	9,368,749
Non-current Liabilities
Lease liabilities, net of current portion	144,532	236,726
Total Liabilities	8,540,408	9,605,475
Commitments and contingencies (See Note 15)
Stockholders’ Equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding at December 31, 2022 and 2021, respectively
Common stock, $0.001 par value, 166,666,667 shares authorized, 18,288,571 and 17,860,975 shares issued at December 31, 2022 and 2021, respectively	18,289	17,861
Treasury stock, $0.001 par value, 1,214,398 and none held at December 31, 2022 and 2021, respectively	(1,214)
Additional paid-in-capital	172,785,800	166,615,514
Accumulated deficit	(46,692,098)	(35,253,658)
Total Stockholders’ Equity	126,110,777	131,379,717
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 134,651,185	$ 140,985,192

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	166,666,667	166,666,667
Common stock, shares issued	18,288,571	17,860,975
Common stock, shares outstanding	18,288,571	17,860,975
Treasury stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Treasury stock, non purchased	1,214,398	1,214,398

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net revenue	$ 62,450,156	$ 61,292,598
Cost of revenues	23,483,336	25,654,384
Gross margin	38,966,820	35,638,214
Operating Expenses
Stock-based compensation	15,745,822	5,491,957
Depreciation, amortization, and noncash lease expense	2,022,029	2,086,454
Other general and administrative expenses	33,489,707	27,698,703
Total operating expenses	51,257,558	35,277,114
Income (loss) from operations	(12,290,738)	361,100
Other income
Interest income	852,298	16,979
Income (loss) before provision for income taxes	(11,438,440)	378,079
Income tax benefit
Net income (loss)	$ (11,438,440)	$ 378,079
Weighted average number of shares outstanding – basic (in Shares)	17,783,992	17,228,019
Weighted average number of shares outstanding – diluted (in Shares)	17,783,992	17,690,489
Income (loss) per share – basic (in Dollars per share)	$ (0.64)	$ 0.02
Income (loss) per share – diluted (in Dollars per share)	$ (0.64)	$ 0.02

Consolidated Statement of Stock

Consolidated Statement of Stockholders’ Equity - USD ($)	Common Stock	Treasury Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2020	$ 15,223		$ 85,590,428	$ (35,631,737)	$ 49,973,914
Balance (in Shares) at Dec. 31, 2020	15,223,340
Stock-based compensation expense
Options			2,709,781		2,709,781
Restricted Stock			2,532,091		2,532,088
Issuance of common stock:
For board compensation	$ 5		250,080		250,085
For board compensation (in Shares)	4,730
Public offering of common shares, net of offering costs	$ 1,524		70,670,012		70,671,536
Public offering of common shares, net of offering costs (in Shares)	1,523,750
Issuance of common stock:
For stock options exercised	$ 1,106		4,863,125		4,864,231
For stock options exercised (in Shares)	1,105,822
For restricted stock units vested	$ 3		(3)		3
For restricted stock units vested (in Shares)	3,333
Net loss for the year				378,079	378,079
Balance at Dec. 31, 2021	$ 17,861		166,615,514	(35,253,658)	131,379,717
Balance (in Shares) at Dec. 31, 2021	17,860,975
Stock-based compensation expense
Options			4,956,619		4,956,619
Restricted Stock			10,789,203		10,789,203
Issuance of common stock:
For stock options exercised	$ 157		1,205,724		1,205,881
For stock options exercised (in Shares)	156,910
For acquisition	$ 241		9,374,214		9,374,455
For acquisition (in Shares)	240,741
For restricted stock units vested	$ 30		(132,430)		(132,400)
For restricted stock units vested (in Shares)	29,945
Repurchase of common stock		$ 1,214	(20,023,044)		(20,021,830)
Repurchase of common stock (in Shares)		(1,214,398)
Net loss for the year				(11,438,440)	(11,438,440)
Balance at Dec. 31, 2022	$ 18,289	$ 1,214	$ 172,785,800	$ (46,692,098)	$ 126,110,777
Balance (in Shares) at Dec. 31, 2022	18,288,571	(1,214,398)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income	$ (11,438,440)	$ 378,079
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	2,022,029	1,965,325
Increase in bad debt reserve	363,512	80,000
Stock-based compensation	15,745,822	5,491,957
Changes in:
Accounts receivable	2,281,773	(6,994,880)
Prepaid expenses and other assets	2,650,951	(1,174,044)
Accounts payable	943,171	(11,442)
Revenue share payable	(387,776)	(591,652)
Accrued expenses and other liabilities	(301,592)	482,475
Change in operating lease liabilities	226	(3,891)
Deferred revenue	(1,225,598)	1,104,112
NET CASH PROVIDED BY OPERATING ACTIVITIES	10,654,078	726,039
CASH FLOWS USED IN INVESTING ACTIVITIES:
Purchases of property and equipment	(81,005)	(100,322)
EvinceMed acquisition	(2,000,000)
Purchase of short-term investments	(55,931,821)
Acquisition of intangible assets, including intellectual property rights	(1,830)	(21,511)
Capitalized software development costs	(161,730)	(364,166)
NET CASH USED IN INVESTING ACTIVITIES	(58,176,386)	(485,999)
CASH FLOWS (USED IN ) / PROVIDED BY FINANCING ACTIVITIES:
Proceeds from public offering of common stock, net of offering costs		70,671,536
Repurchase of common stock	(20,024,258)
Proceeds from exercise of stock options, net of cash paid for withholding taxes	1,073,481	4,864,231
Payment of contingent consideration		(1,610,813)
NET CASH (USED IN) / PROVIDED BY FINANCING ACTIVITIES	(18,950,777)	73,924,954
NET (DECREASE) / INCREASE IN CASH AND CASH EQUIVALENTS	(66,473,085)	74,164,994
CASH AND CASH EQUIVALENTS – BEGINNING OF PERIOD	84,681,770	10,516,776
CASH AND CASH EQUIVALENTS – END OF PERIOD	18,208,685	84,681,770
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest
Reduction of EvinceMed purchase price for amounts previously paid	708,334
Shares issued in connection with acquisition	9,374,455
Cash paid for income taxes

Organization and Nature of Busi

Organization and Nature of Business	12 Months Ended
	Dec. 31, 2022
Organization and Nature of Business [Abstract]
ORGANIZATION AND NATURE OF BUSINESS	NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS OptimizeRx is a digital health technology company enabling care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over 60% of U.S. healthcare providers and millions of their patients through an intelligent technology platform embedded within a proprietary point-of-care network, OptimizeRx helps patients start and stay on their medications.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions have been made in determining the carrying value of assets, depreciable and amortizable lives of tangible and intangible assets, the carrying value of liabilities, the valuation allowance for the deferred tax asset, the timing of revenue recognition and related revenue share expenses, and inputs used in the calculation of stock based compensation. Actual results could differ from these estimates. Principles of Consolidation The financial statements reflect the consolidated results of OptimizeRx Corporation, a Nevada corporation, and its wholly owned subsidiaries: OptimizeRx Corporation, a Michigan corporation, CareSpeak Communications, Inc., a New Jersey corporation, Cyberdiet, a controlled foreign corporation incorporated in Israel, and CareSpeak Communications D.O.O., a Controlled Foreign Corporation incorporated in Croatia. Together, these companies are referred to as “OptimizeRx” and “the Company.” All material intercompany transactions have been eliminated. Reclassifications Certain items in the previous year financial statements have been reclassified to match the current year presentation. Foreign Currency The Company’s functional currency is the U.S. dollar, however it pays certain expenses related to its two foreign subsidiaries in the local currency, which is the shekel for its subsidiary in Israel and the kuna for its Croatian subsidiary. All transactions are recorded at the exchange rate at the time of payment. If there is a time lag between the time of recording the liability and the time of payment, a gain or loss is recorded in the Consolidated Statement of Operations due to any fluctuations in the exchange rate. Cash and Cash Equivalents For purposes of the accompanying financial statements, the Company considers all highly liquid instruments, consisting of money market accounts, with an initial maturity of three months or less to be cash equivalents. Investments We account for marketable securities in accordance with ASC 320, “Investments - Debt Securities”, which require that certain debt securities be classified into one of three categories: held-to-maturity, available-for-sale, or trading securities, and depending upon the classification, value the security at amortized cost or fair market value. Fair Value of Financial Instruments Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The fair value should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the fair value of liabilities should include consideration of non-performance risk including our own credit risk. In addition to defining fair value, the disclosure requirements around fair value establish a fair value hierarchy for valuation inputs, which is expanded. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels, which is determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are: Level 1 – Inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. Level 2 – Inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. The Company’s stock options and warrants are valued using level 3 inputs. The Company’s carrying amounts of financial instruments including cash and cash equivalents, accounts receivable, accounts payable, and other current liabilites approximate their fair values due to their short maturities. Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are reported at realizable value, net of allowances for doubtful accounts, which is estimated and recorded in the period the related revenue is recorded. The Company has a standardized approach to estimate and review the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to allowances for doubtful accounts. In addition, the Company regularly assesses the state of its billing operations in order to identify issues, which may impact the collectability of these receivables or reserve estimates. Because the Company’s customers are primarily large well-capitalized companies, historically there has been very little bad debt expense. Bad debt expense was $363,512 for the year ended December 31, 2022 and $80,000 for the year ended December 31, 2021. The allowance for doubtful accounts was $352,043 and $241,219 as of December 31, 2022 and 2021, respectively. From time to time, we may record revenue based on our revenue recognition policies described below in advance of being able to invoice the customer. Included in accounts receivable are unbilled amounts of $3,582,735,$2,110,865 and $757,218 at December 31, 2022, 2021 and 2020, respectively. Property and Equipment Property and equipment are stated at cost and are being depreciated over their estimated useful lives of three to five years for office equipment and three years for computer equipment using the straight-line method of depreciation for book purposes. Maintenance and repair charges are expensed as incurred. Intangible Assets Intangible assets are stated at cost. Finite-lived assets are being amortized over their estimated useful lives of fifteen to seventeen years for patents, eight years for customer relationships, fifteen years for tradenames, two to four years for covenants not to compete, and three to ten years for software and websites, all using the straight-line method. These assets are evaluated when there is a triggering event. There was no impairment of our intangible assets in either year presented. Goodwill We evaluate goodwill for impairment during our fiscal fourth quarter, or more frequently if an event occurs or circumstances change. Our analysis determined that there was no impairment of our goodwill. Revenue Recognition Recognition of revenue requires evidence of a contract, probable collection of proceeds, and completion of substantially all performance obligations. We use a 5-step model to recognize revenue. These steps are: identify the contract with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize revenue when or as the performance obligations are satisfied. Revenues are primarily generated from content delivery activities in which the Company delivers financial, clinical, or brand messaging through a distribution network of eprescribers and electronic health record technology providers (channel partners), directly to consumers, or from reselling services that complement the business. This content delivery for a customer is referred to as a program. Unless otherwise specified, revenue is recognized based on the selling price to customers. The Company’s contracts are generally all less than one year and the primary performance obligation is delivery of messages, or content, but the contract may contain additional services. Additional services may include program design, which is the design of the content delivery program, set up, and reporting. We consider set up and reporting services to be complimentary to the primary performance obligation and recognized through performance of the delivery of content. We consider program design and related consulting services to be performance obligations separate from the delivery of messages. As the content is distributed through the platform and network of channel partners (a transaction), these transactions are recorded, and revenue is recognized over time as the distributions occur. Revenue for transactions can be realized based on a price per message, a price per redemption, as a flat fee occurring over a period of time, or upon completion of the program, depending on the client contract. The Company recognizes setup fees that are required for integrating client offerings and campaigns into the rule-based content delivery system and network over the life of the initial program, based either on time, or units delivered, depending upon which is most appropriate in the specific situation. Should a program be cancelled before completion, the balance of set up revenue is recognized at the time of cancellation, as set up fees are nonrefundable. Additionally, the Company also recognizes revenue for providing program performance reporting and maintenance, either by the Company directly delivering reports or by providing access to its online reporting portal that the client can utilize. This reporting revenue is recognized over time as the messages are delivered. Program design, which is the design of the content delivery program, and related consulting services are recognized as services are performed. Disaggregation of Revenue Consistent with ASC Topic 606, we have disaggregated our revenue by timing of revenue recognition. The majority of our revenue is recognized over time as solutions are provided. A small portion of our revenue related to program development, solution architect design, and other solutions is recognized at a point in time upon delivery to customers. A break down is set forth in the table below. 2022 2021 Revenue recognized over time $ 55,437,418 $ 57,077,743 Revenue recognized at a point in time 7,012,738 4,214,855 Total Revenue $ 62,450,156 $ 61,292,598 Revenue Recognition (Continued) In some instances, we license certain of our software applications in arrangements that do not include other performance obligations. In those instances, we record license revenue when the software is delivered for use to the license. In instances where our contracts included Software as a Service, the revenue is recognized over the subscription period as services are delivered to the customer. In some instances, the Company also resells messaging solutions that are available through channel partners that are complementary to the core business and client base. These partner specific solutions are frequently similar to our own solutions and revenue recognition for these programs is the same as described above. In instances where the Company sells solutions on a commission basis, net revenue is recognized based on the commission-based revenue split that the Company receives. There were no programs recorded on a net basis in the years presented. In instances where the Company resells these messaging solutions and has all financial risk and significant operation input and risk, the Company records the revenue based on the gross amount sold and the amount paid to the channel partner as a cost of sales. Cost of Revenues The primary cost of revenue is revenue share expense. Cost of revenues does not include depreciation and amortization which is listed separately on the statements of operations. Based on the volume of transactions that are delivered through the channel partner network, the Company provides a revenue share to compensate the partner, or others, for their promotion of the campaign. Revenue shares are a negotiated percentage of the transaction fees and can also be specific to special considerations and campaigns. Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. The Company recognizes the tax benefit from uncertain tax positions if it is more likely than not that the tax positions will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefit is measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. It is the Company’s policy to include interest and penalties related to tax positions as a component of income tax expense. Concentration of Credit Risks The Company maintains its cash and cash equivalents in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts; however, amounts in excess of the federally insured limit may be at risk if the bank experiences financial difficulties. As of December 31, 2022 and 2021 the Company had $15,669,837 and $83,312,524, respectively, in cash balances in excess of federally insured limits, primarily at Bank of America. Research and Development The Company expenses research and development expenses as incurred. There was no research and development expense for the years ended December 31, 2022 and 2021. Stock-based Compensation The Company uses the fair value method to account for stock-based compensation. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital over the period during which services are rendered. The fair value of each award is estimated on the date of each grant. For restricted stock awards, the fair value is based on the market value of the Company’s common stock on the date of grant. For market based restricted stock units, the fair value is estimated using a Monte Carlo simulation model. This valuation technique includes estimating the movement of stock prices and the effects of volatility, interest rates and dividends. For options, fair value is estimated using the Black-Scholes option pricing model that uses the following assumptions. Estimated volatilities are based on the historical volatility of the Company’s common stock over the same period as the expected term of the options. The expected term of options granted represents the period of time that options granted are expected to be outstanding. The Company uses historical data to estimate option exercise behavior and to determine this term. The risk-free rate used is based on the U.S. Treasury yield curve in effect at the time of the grant using a time period equal to the expected option term. The Company has never paid dividends and do not expect to pay any dividends in the future. 2022 2021 Expected dividend yield 0 % 0 % Risk free interest rate 0.82% - 4.38% 0.19% - 0.67% Expected option term 3.5 years 3.5 years Turnover/forfeiture rate 0 % 0 % Expected volatility 68% - 71% 67% - 70% Weighted average grant date fair value $ 12.82 $ 26.36 The Black-Scholes option valuation model and other existing models were developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. These option valuation models require the input of, and are highly sensitive to, subjective assumptions including the expected stock price volatility. The Company’s stock options have characteristics significantly different from those of traded options, and changes in the subjective input assumptions could materially affect the fair value estimate. Loss Per Common and Common Equivalent Share The computation of basic (loss) earnings per common share is computed using the weighted average number of common shares outstanding during the year. The computation of diluted (loss) earnings per common share is based on the basic weighted average number of shares outstanding during the year plus common stock equivalents, which would arise from the exercise of options and warrants outstanding using the treasury stock method and the average market price per share during the year. The number of common shares potentially issuable upon the exercise of certain awards that were excluded from the diluted loss per common share calculation in 2022 was 93,626 related to options, and 170,859 related to restricted stock units, for a total of 264,485 because they are anti-dilutive, as a result of a net loss for the year ended December 31, 2022. The computation of weighted average shares outstanding and the basic and diluted earnings per common share for the years ended December 31, 2022 and 2021 consisted of the following: Year ended December 31, 2022 Net (Loss) Shares Per Share Basic EPS $ (11,438,440 ) 17,783,992 $ (0.64 ) Effect of dilutive securities — — — Diluted EPS $ (11,438,440 ) 17,783,992 $ (0.64 ) Year ended December 31, 2021 Net Income Shares Per Share Basic EPS $ 378,079 17,228,019 $ 0.02 Effect of dilutive securities 462,470 — Diluted EPS $ 378,079 17,690,489 $ 0.02 Impairment of Long-Lived Assets The Company continually monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell. Segment reporting We operate in one reportable segment. Overall, our business involves connecting life science companies to patients and providers. We have a common customer base for all of our solutions, which are primarily all communications with healthcare providers or patients on behalf of life science customers. Our customers are geographically located in the U.S although we have two technology centers located internationally. We do not prepare separate internal income statements by solutions as our focus is on selling enterprise arrangements covering multiple solutions that span the entire patient journey with a specific brand. Recently Issued Accounting Guidance In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes Not Yet Adopted ASU Topic 2021-08 Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2022
Acquisitions [Abstract]
ACQUISITIONS	NOTE 3 – ACQUISITIONS On April 14, 2022, we completed the acquisition of substantially all of the assets of EvinceMed Corp., a privately held leading provider of delivering end-to-end automation for specialty pharmaceutical transactions. We completed the acquisition to expand the breadth of the solutions we offer our customers, particularly where specialty medications are involved, The acquisition included the full Market Access Management Platform for supporting pharma manufacturers, hub providers and pharmacies to improve patient access, speed to therapy and activation of affordability programs. With the EvinceMed platform, OptimizeRx is able to help patients get access to the drugs they need by simplifying the prescribing process for specialty medications, automating manual steps to determine drug eligibility and affordability, and introducing electronic enrollment and medical documentation across The consideration was comprised of $2.0 million in cash, the issuance of 240,741 shares of common stock valued at $9,374,455, and $708,334 of amounts previously paid. The total purchase price was $12,082,789. Of the 240,741 shares of common stock, 185,185 were issued at closing and 55,556 were issued but held back to secure potential adjustments to the purchase price that may result from the indemnification obligations of EvinceMed and the EvinceMed shareholder indemnitors. The holdback amount will be released twelve months from the closing, subject to any adjustments for the payment by EvinceMed and the shareholder indemnitors for its and their indemnification obligations. The purchase price was allocated to acquired technology totaling $4,149,000 with an estimated useful life of 8 years and the remaining $7,933,789 was allocated to goodwill. Goodwill represents the processes and synergies expected by integrating those processes with our own. The full amount of goodwill will be deductible for tax purposes using a 15 year life. The increase in goodwill for the period is fully accounted for by this acquisition. We determined pro forma data was immaterial for financial reporting purposes. The initial accounting is provisional and subject to change based on the completion of formal valuations. Acquisition costs of approximately $19,739 were expensed as incurred.

Investment Securities

Investment Securities	12 Months Ended
	Dec. 31, 2022
Investment Securities [Abstract]
INVESTMENT SECURITIES	NOTE 4 – INVESTMENT SECURITIES At December 31, 2022 the Company held $55.9 million in U.S. government and agency securities. All securities have maturity dates of less than one year. The Company reports them at amortized cost. The amortized cost approximates fair value at December 31, 2022 due to the short nature of the securities. There were no securities held at December 31, 2021.

Prepaid Expenses

Prepaid Expenses	12 Months Ended
	Dec. 31, 2022
Prepaid Expenses [Abstract]
PREPAID EXPENSES	NOTE 5 – PREPAID EXPENSES Prepaid expenses consisted of the following as of December 31, 2022 and 2021: 2022 2021 Revenue share and exclusivity payments $ 1,025,000 $ 4,516,668 Software 408,063 181,044 Insurance 221,580 156,327 Data 152,533 168,462 Other 473,652 608,154 Total prepaid expenses $ 2,280,828 $ 5,630,655

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 6 – PROPERTY AND EQUIPMENT The Company owned equipment recorded at cost, which consisted of the following as of December 31, 2022 and 2021: 2022 2021 Computer equipment $ 230,467 $ 267,917 Furniture and fixtures 38,500 200,250 268,967 468,167 Less accumulated depreciation 131,519 324,349 Property and equipment, net $ 137,448 $ 143,818 Depreciation expense was $85,725 and $105,360 for the years ended December 31, 2022 and 2021, respectively.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 7 – INTANGIBLE ASSETS Goodwill Our goodwill is related to the acquisitions of EvinceMed in 2022, RMDY Health, Inc. in 2019 and CareSpeak Communications in 2018. Goodwill is not amortizable for financial statement purposes. Changes in the carrying amount of goodwill on the consolidated balance sheet consist of the following: Balance at January 1, 2021 $ 14,740,031 Acquisitions - Impairments - Balance January 1, 2022 $ 14,740,031 Revenue recognized 7,933,789 Amount collected - Balance December 31, 2022 $ 22,673,820 Intangible Assets Intangible assets included on the consolidated balance sheets consist of the following: December 31, 2022 Gross Accumulated Net Weighted Patent rights $ 3,364,729 $ 1,424,551 $ 1,940,178 8.5 Technology assets 12,859,660 5,156,765 7,702,895 5.1 Other intangible assets Tradename 3,586,000 776,966 2,809,034 11.7 Non-compete agreements 1,093,000 1,093,000 — 0 Customer relationships 923,000 352,196 570,804 7.4 Total other 5,602,000 2,222,162 3,379,838 Total intangible assets $ 21,826,389 $ 8,803,478 $ 13,022,911 December 31, 2021 Gross Accumulated Net Weighted Patent rights $ 3,362,898 $ 1,207,872 $ 2,155,026 9.6 Technology assets 8,548,930 3,959,804 4,589,126 4.9 Other intangible assets Tradename 3,586,000 537,900 3,048,100 12.7 Non-compete agreements 1,093,000 899,635 193,365 0.6 Customer relationships 923,000 261,963 661,037 8.4 Total other 5,602,000 1,699,498 3,902,502 Total intangible assets $ 17,513,828 $ 6,867,174 $ 10,646,654 Intangibles are being amortized on a straight-line basis over the following estimated useful lives. Patents 15 – 17 years Tradenames 15 years Non-compete agreements 2 – 4 years Customer relationships 8 years Technology assets 3 – 10 years The Company recorded amortization expense of $1,936,304 and $1,859,965 in the years ended December 31, 2022 and 2021, respectively. Expected future amortization expense of the intangibles assets as of December 31, 2022 is as follows: Year ended December 31, 2023 $ 1,769,212 2024 1,769,212 2025 1,682,054 2026 1,566,184 2027 1,483,765 Thereafter 4,752,484 Total $ 13,022,911

Deferred Revenue

Deferred Revenue	12 Months Ended
	Dec. 31, 2022
Revenues [Abstract]
DEFERRED REVENUE	NOTE 8 – DEFERRED REVENUE The Company has several signed contracts with customers for the distribution of financial messaging, or other services, which include payment in advance. The payments are not recorded as revenue until the revenue is earned under its revenue recognition policy discussed in Note 2. Deferred revenue was $164,309 and $1,389,907 as of December 31, 2022 and 2021, respectively. These contracts are all short term in nature and all revenue is expected to be recognized within 12 months, or less. Following is a summary of activity in the deferred revenue account for the year ended December 31, 2022. Balance January 1, 2022 $ 1,389,907 Revenue recognized (36,346,653 ) Amount collected 35,121,055 Balance December 31, 2022 $ 164,309 Following is a summary of activity in the deferred revenue account for the year ended December 31, 2021. Balance January 1, 2021 $ 285,795 Revenue recognized (18,006,973 ) Amount collected 19,111,085 Balance December 31, 2021 $ 1,389,907

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 9 – RELATED PARTY TRANSACTIONS During the year ended December 31, 2010, the Company acquired the technical contributions and assignment of all exclusive rights to and for a key patent in process at the time from a former CEO in exchange for a total payment in shares of common stock and options valued at $930,000 at the time of the acquisition and recorded the patent at that cost. That patent remains in Patents on the consolidated balance sheet as of December 31, 2022. Jim Lang, one of our Board Members, is the CEO of Eversana, a leading global provider of services to the life sciences industry. Eversana is similar to other customers we generate revenue from, such as agencies or resellers. During the years ended December 31, 2022 and 2021, respectively, we have recognized $401,972 and $218,333 in revenue from contracts engaged with Eversana. These contracts were sourced by Eversana on behalf of life science customers of theirs. The contracts are at market rates and were generated in the normal course of business.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2022
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY	NOTE 10 – STOCKHOLDERS’ EQUITY Preferred Stock The Company had 10,000,000 shares of preferred stock, $0.001 par value per share, authorized as of December 31, 2022. No shares were issued or outstanding in either 2021 or 2022. Common Stock The Company had 166,666,667 shares of common stock, $0.001 par value per share, authorized as of December 31, 2022. There were 17,074,173 and 17,860,975 shares of common stock outstanding, net of shares held in treasury, at December 31, 2022 and 2021, respectively. We issued 156,910 shares of common stock and received proceeds of $1,205,881 in 2022 in connection with the exercise of options. We also issued 1,105,822 shares of common stock and received proceeds of $4,864,231 in 2021 in connection with the exercise of options. We issued 29,945 shares of common stock in 2022 and 3,333 shares of common in stock in 2021 in connection with the vesting of restricted stock units and discussed in greater detail in Note 11, Stock Based Compensation. The Company had a Director Compensation plan covering its independent non-employee Directors that was in effect through June 30, 2021. A total of 4,730 were granted and issued in the year ended December 31, 2021 in connection with this compensation plan. These shares were valued at $250,085. The plan was changed to grant restricted stock units under the Company’s 2021 Equity Incentive Plan and those grants are discussed in Note 10, Stock Based Compensation. During the year ended December 31, 2021, in an underwritten primary offering, we issued 1,523,750 shares of our common stock for gross proceeds of $75,425,625. In connection with this transaction, we incurred equity issuance costs of $4,754,089 related to payments to the underwriter, advisors and legal fees associated with the transaction, resulting in net proceeds to the Company of $70,671,536. During the year ended December 31, 2022, the Board authorized a share repurchase program, under which the Company may repurchase up to $20.0 million of its outstanding common stock. Through December 31, 2022, we repurchased 1,214,398 shares of our common stock for a total of $20,024,258, including commissions paid on repurchases. These shares were recorded as Treasury Shares using the par value method.

Stock Based Compensation

Stock Based Compensation	12 Months Ended
	Dec. 31, 2022
Stock Based Compensation [Abstract]
STOCK BASED COMPENSATION	NOTE 11 – STOCK BASED COMPENSATION The Company sponsors two stock-based incentive compensation plans. The first plan is known as the 2013 Incentive Plan (the “2013 Plan”) and was established by the Board of Directors of the Company in June 2013. The 2013 Plan, as amended, authorized the issuance of 3,000,000 shares of Company common stock. The amended plan was approved by shareholders. A total of 410,701 shares of common stock underlying options and 128,590 shares of common stock underlying restricted stock unit awards were outstanding at December 31, 2022. In connection with the adoption of a new plan in 2021, the Company froze the 2013 Plan. At December 31, 2022, there were no shares available for grant under the 2013 Plan. In 2021, the Company adopted a new plan known as the 2021 Equity Incentive Plan (“2021 Plan”). The plan was established by the Board of Directors and approved by shareholders in August 2021. A total of 2,500,000 shares are authorized for issuance under the 2021 Plan. A total of 896,169 shares of common stock underlying options and 660,484 shares of common stock underlying restricted stock unit awards were outstanding at December 31, 2022. At December 31, 2022, 921,946 shares were available for grant under the 2021 Plan. The 2021 Plan allows the Company to grant incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards and other stock-based awards. Incentive stock options may only be granted to persons who are regular full-time employees of the Company at the date of the grant of the option. Non-qualified options may be granted to any person, including, but not limited to, directors, officers, employees and consultants, who the Company’s Board or Compensation Committee determines. The exercise price of options granted under the 2021 Plan must be equal to at least 100% of the fair market value of our common stock as of the date of the grant of the option. Options granted under the 2021 Plan are exercisable as determined by the Compensation Committee and specified in the applicable award agreement. In no event will an option be exercisable after ten years from the date of grant. Stock Options The compensation cost that has been charged against income related to options for the years ended December 31, 2022 and 2021, was $4,956,619 and $2,709,781, respectively. No income tax benefit was recognized in the consolidated statements of income and no compensation was capitalized in any of the years presented. During the year ended December 31, 2022, we granted certain performance based options, the expense for which will be recorded over time once the achievement of the performance is deemed probable. There was no expense related to these options recorded during the period. The fair value of these instruments was calculated using the Black-Scholes option pricing model. In the year ended December 31, 2021, certain participants utilized a net withhold exercise method in which options were surrendered to cover payroll withholding tax. Of the cumulative net options exercised by participants were 31,243 options, valued at $100,290, were surrendered and subsequently cancelled. The Company had the following option activity during the year ended December 31, 2022 and 2021: Number of Options Weighted average exercise price Weighted average remaining contractual life (years) Aggregate intrinsic Outstanding at January 1, 2021 1,545,518 $ 7.31 Granted 424,588 $ 54.34 Exercised (1,105,822 ) $ 7.33 Withheld and cancelled (31,243 ) 3.21 Expired or forfeited (49,494 ) $ 24.57 Outstanding at December 31, 2021 783,547 $ 34.17 3.4 $ 23,368,961 Granted 862,938 $ 25.43 Exercised (156,910 ) $ 7.69 Expired or forfeited (182,705 ) $ 37.13 Outstanding, December 31, 2022 1,306,870 $ 31.14 2.7 $ 1,537,752 Exercisable, December 31, 2022 250,684 $ 33.82 2.6 $ 538,652 The table below reflects information for the total options outstanding at December 31, 2022 Range of Exercise Prices Number of Options Weighted average remaining contractual life (years) Weighted average exercise price $4.20 to $10.00 30,335 1.5 $ 6.40 $10.00 to $20.00 568,358 2.6 $ 14.66 $20.00 to $40.00 322,916 2.6 $ 33.79 $40.00 to $60.00 284,231 2.8 $ 47.99 $60.00 to $96.70 101,030 3.7 $ 75.43 Total 1,306,870 2.7 $ 31.14 The table below reflects information for the vested options outstanding at December 31, 2022. Range of Exercise Prices Number of Options Weighted average remaining contractual life (years) Weighted average exercise price $4.20 to $10.00 24,168 1.3 $ 6.22 $10.00 to $20.00 69,868 1.7 $ 12.84 $20.00 to $40.00 69,170 2.9 $ 30.77 $40.00 to $60.00 54,667 3.3 $ 51.54 $60.00 to$96.70 32,811 3.7 $ 75.74 Total 250,684 2.6 $ 33.82 A summary of the status of the Company’s nonvested options as of December 31, 2022, and changes during the year ended December 31, 2022, is presented below. Nonvested Options Options Weighted average exercise price Nonvested at January 1, 2022 586,276 $ 42.01 Granted 862,938 $ 25.43 Vested (223,323 ) $ 35.04 Forfeited (169,705 ) $ 37.83 Nonvested at December 31, 2022 1,056,186 $ 30.51 There is $12,528,706 of expense remaining to be recognized over a period of approximately 2.1 years related to options outstanding at December 31, 2022. Restricted Stock Units The Company had the following restricted stock unit (“RSU”) activity during the years ended December 31, 2022 and 2021: Number of RSUs Weighted average grant date fair value Weighted average remaining contractual life (years) Outstanding at January 1, 2021 100,000 $ 11.51 Granted 303,556 $ 66.30 Forfeited (485 ) $ 61.82 Shares issued (3,333 ) $ 21.20 Outstanding at December 31, 2021 399,738 $ 52.99 3.3 Granted 467,043 $ 25.69 Forfeited (39,346 ) $ 44.06 Vested and issued (29,945 ) $ 59.41 Withheld and cancelled (8,416 ) $ 68.69 Outstanding at December 31, 2022 789,074 $ 36.95 2.0 The Company granted restricted stock units of 467,043 and 303,556 units in 2022 and 2021, respectively, and valued at $11,996,111 and $20,125,861, respectively. These restricted stock units vest over a period of 1 year to 5 years. The Company recognized expense of $10,789,203 and $2,532,091 in 2022 and 2021, respectively, related to these restricted stock units. A total of $17,862,951 remains to be recognized at December 31, 2022 over a period of 2.0 years. In the year ended December 31, 2022, certain participants utilized a net withhold settlement method, in which shares were surrendered to cover payroll withholding tax. Of the cumulative net options exercised by participants were 31,243 options, valued at $100,290, were surrendered and subsequently cancelled. Performance Stock Units Of the restricted stock units issued in 2021, 182,938 are market-based awards that vest if the Company’s stock price hits certain price targets and maintains that price for 30 days. A total of 60,191, 60,191, and 62,016 units vest if the stock price hits $98.87, $131.82, and $164.78, respectively. As described in Note 2, these market-based restricted stock units were valued using a Monte Carlo simulation model, with expected vesting in 1.60, 2.25, and 2.71 years, respectively, for the three price targets. During the year ended December 31, 2022, we granted certain performance based stock units, the expense for which will be recorded over time once the achievement of the performance is deemed probable. There was no expense related to these options recorded during the period. Non-employee Directors’ Compensation Our previous director’s compensation plan called for the issuance of fully-vested shares of common stock each quarter to each independent director. In 2021, we issued 4,730 shares valued at $250,085 that immediately vested. Subsequent to these grants, we adopted a new directors compensation program that calls for the grant of restricted stock units with a one year vesting period. We granted 3,715 restricted stock units valued at $250,175 in the second half of 2021 under the new plan. These restricted stock units vested in 2022. There were 26,470 restricted stock units, valued at $750,130, granted to the board of directors in 2022 that will vest in 2023, 12 months from the grant dates.

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
LEASES	NOTE 12 – LEASES In February 2016, the Financial Accounting Standards Board (“FASB”) issued new accounting guidance on leases. The accounting standard, effective January 1, 2019, requires virtually all leases to be recognized on the balance sheet. Under the guidance, we have elected not to separate lease and non-lease components in recognition of the lease-related assets and liabilities, as well as the related lease expense. We had operating leases with terms greater than 12 months for office space in three multitenant facilities, which are recorded as assets and liabilities. The lease on our headquarters space in Rochester, Michigan expires November 30, 2023, with a renewal option through 2025, with monthly rent payable at rates ranging from $6,384 to $6,688. We have assumed renewal of the lease. We also had a lease on office space in Cranbury, New Jersey, which expired in January 2022 with a monthly payment of $3,158, as well as a lease of approximately $1,883 per month in Zagreb, Croatia expiring in 2024. Lease-related assets, or right-of-use assets, are recognized at the lease commencement date at amounts equal to the respective lease liabilities, adjusted for prepaid lease payments, initial direct costs, and lease incentives received. Lease-related liabilities are recognized at the present value of the remaining contractual fixed lease payments, discounted using our incremental borrowing rate. Operating lease expense is recognized on a straight-line basis over the lease term, while variable lease payments are expensed as incurred. For the years ended December 31, 2022 and 2021, the Company’s lease cost consisted of the following components, each of which is included in operating expenses within the Company’s consolidated statements of operations: 2022 2021 Operating lease cost $ 100,771 $ 132,305 Short-term lease cost (1) 75,784 52,375 Total lease cost $ 176,555 $ 184,680 (1) Short-term lease cost includes any lease with a term of less than 12 months. The table below presents the future minimum lease payments to be made under operating leases as of December 31, 2022: For the year ending December 31, 2023 $ 98,247 2024 80,215 2025 70,224 Total 248,686 Less: present value discount 14,252 Total lease liabilities $ 234,434 The weighted average remaining lease term for operating leases is 2.7 years and the weighted average discount rate used in calculating the operating lease asset and liability is 4.5%. Cash paid for amounts included in the measurement of lease liabilities was $89,111. For the year ended December 31, 2022, payments on lease obligations were $101,405 and amortization on the right of use assets was $101,433. For the year ended December 31, 2021, payments on lease obligations were $142,284 and amortization on the right of use assets was $121,129.

Major Customers and Vendors

Major Customers and Vendors	12 Months Ended
	Dec. 31, 2022
Risks and Uncertainties [Abstract]
MAJOR CUSTOMERS AND VENDORS	NOTE 13 – MAJOR CUSTOMERS AND VENDORS The Company had the following customers that accounted for 10% or greater of revenue in either 2022 or 2021. No other customers accounted for more than 10% of revenue in either year presented. 2022 2021 $ % $ % Customer A 6,817,682 10.9 5,206,305 8.5 Customer B 3,876,580 6.2 14,268,819 23.0 Our accounts receivable included two entities, including one agency that represented multiple customers, that individually made up more than 10% of our accounts receivable at December 31, 2022 in the percentages of 13.3% and 10.8%. As of December 31, 2021, our accounts receivable included two agencies that represented multiple customers that individually made up more than 10% of our accounts receivable in the percentages of 33.5% and 12.2%. The Company generates its revenues through its EHR and ePrescribe partners. There were three key partners and/or vendors through which 10% or greater of its revenue was generated in either 2022 or 2021 as set forth below. The amounts in the table below reflect the amount of revenue generated through those partners. 2022 2021 $ % $ % Partner A 19,882,511 31.8 33,041,503 53.9 Partner B 12,494,227 20.0 2,761,893 4.5 Partner C 6,578,661 10.5 9,554,266 15.6

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 14 – INCOME TAXES As of December 31, 2022, the Company had net operating loss (“NOLs”) carry-forwards for federal income tax purposes of approximately $21.5 million, consisting of pre-2018 losses in the amount of approximately $8.2 million that expire from 2022 through 2037, and post-2017 losses in the amount of approximately $13.3 million that will never expire. These net operating losses are available to offset future taxable income. The Company was formed in 2008 as a Nevada Corporation. Activity prior to incorporation is not reflected in the Company’s corporate tax returns. In the future, the cumulative net operating loss carry-forward for income tax purposes may differ from the cumulative financial statement loss due to timing differences between book and tax reporting. The provision for Federal income tax consists of the following for the years ended December 31, 2022 and 2021: 2022 2021 Federal income tax benefit (expense) attributable to: Current operations $ 2,402,000 $ (79,000 ) State tax effect, net of federal benefit 545,000 979,000 Option exercise benefits (expenses), net of Section 162M limitations (268,000 ) 2,171,000 Other adjustments 221,000 (30,000 ) NOLs expiring — (26,000 ) Valuation allowance (2,900,000 ) (3,006,000 ) Net provision for federal income tax $ — $ — 2022 2021 Current tax benefit (expense) - Federal $ — $ — Deferred tax benefit (expense) - Federal — — Adjustment of valuation allowance from business combination — — Total tax benefit (expense) on income $ — $ — The cumulative tax effect of significant items comprising our net deferred tax amount at the expected rate of 21% is as follows as of December 31, 2022 and 2021: 2022 2021 Deferred tax asset attributable to: Net operating loss carryover $ 5,545,000 $ 6,887,000 Stock compensation 3,953,000 809,000 Operating lease liability 63,000 88,000 Section 174 Capitalized Expenses 789,000 — Fixed Assets 126,000 13,000 Other 16,000 85,000 Deferred tax asset $ 10, 492,000 $ 7,882,000 Deferred tax liabilities attributable to: Intangibles $ (2,102,000 ) $ (2,490,000 ) Operating lease right of use assets (63,000 ) (88,000 ) Goodwill (106,000 ) — Other (59,000 ) (42,000 ) Deferred tax liability (2,330,000 ) (2,620,000 ) Net deferred tax asset $ 8,162,000 $ 5,262,000 Valuation allowance (8,162,000 ) (5,262,000 ) Net deferred tax asset, net of valuation allowance $ — $ — The ultimate realization of deferred tax assets is dependent upon the Company’s ability to generate sufficient taxable income during the periods in which the net operating losses expire and the temporary differences become deductible. The Company has determined that there is significant uncertainty that the results of future operations and the reversals of existing taxable temporary differences will generate sufficient taxable income to realize the deferred tax assets; therefore, a valuation allowance has been recorded. In making this determination, the Company considered historical levels of income, projections for future periods, and the significant amount of tax deductions to be generated from the future exercise of stock options. The tax years 2019 to 2022 remain open for potential audit by the Internal Revenue Service. There are no uncertain tax positions as of December 31, 2021 or December 31, 2022, and none are expected in the next 12 months. The Company’s foreign subsidiaries are cost centers that are primarily reimbursed for expenses, as a result they generate an immaterial amount of income or loss. Pretax book income (loss) is all from domestic operations. Up to four years of returns remain open for potential audit in foreign jurisdictions, however any audits for periods prior to ownership by the Company are the responsibility of the previous owners. Under certain circumstances issuance of common shares can result in an ownership change under Internal Revenue Code Section 382, which limits the Company’s ability to utilize carry-forwards from prior to the ownership change. Any such ownership change resulting from stock issuances and redemptions could limit the Company’s ability to utilize any net operating loss carry-forwards or credits generated before this change in ownership. These limitations can limit both the timing of usage of these laws, as well as the loss of the ability to use these net operating losses. The Company had an ownership change as described in IRC Section 382 on March 18, 2014. The Company NOL’s generated up until March 18, 2014 have been fully released.

Commitments and Contingent Liab

Commitments and Contingent Liabilities	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	NOTE 15 – COMMITMENTS AND CONTINGENT LIABILITIES Legal The Company is not involved in any legal proceedings. Revenue-share contracts The Company has contracts with various electronic health records systems and ePrescribe platforms, whereby we agree to share a portion of the revenue we generate for eCoupons distributed and banners delivered through their networks. These contracts grant audit rights related to the payments to our partners, and, in some cases would require us to pay for the audit if the audit determined there was an underpayment and the underpayment meets certain thresholds, such as 10%. From time to time the Company enters into arrangements with a partner to acquire minimum amounts of messaging capabilities. As of December 31, 2022, the Company had commitments for future minimum payments of $16.4 million that will be reflected in cost of revenues during the years from 2023 through 2025. Minimum payments are due in 2023, 2024 and 2025, in the amounts of $6.2 million, $5.2 million and $5.0 million, respectively.

Retirement Plan

Retirement Plan	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
RETIREMENT PLAN	NOTE 16 – RETIREMENT PLAN The Company sponsors a defined contribution 401(k) profit sharing plan which was adopted in December 2015, effective in January 2016. Under the terms of the plan, the Company matches 100% of the first 3% of payroll contributed by the employee and 50% of the next 2% of payroll contributed by the employee to a maximum of 4% of an employee’s payroll. There was expense of $489,780 and $343,221 recorded in 2022 and 2021, respectively, for the Company’s contributions to the plan.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 17 – SUBSEQUENT EVENTS None.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2022
New Accounting Standards [Abstract]
Basis of Presentation	Basis of Presentation The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions have been made in determining the carrying value of assets, depreciable and amortizable lives of tangible and intangible assets, the carrying value of liabilities, the valuation allowance for the deferred tax asset, the timing of revenue recognition and related revenue share expenses, and inputs used in the calculation of stock based compensation. Actual results could differ from these estimates.
Principles of Consolidation	Principles of Consolidation The financial statements reflect the consolidated results of OptimizeRx Corporation, a Nevada corporation, and its wholly owned subsidiaries: OptimizeRx Corporation, a Michigan corporation, CareSpeak Communications, Inc., a New Jersey corporation, Cyberdiet, a controlled foreign corporation incorporated in Israel, and CareSpeak Communications D.O.O., a Controlled Foreign Corporation incorporated in Croatia. Together, these companies are referred to as “OptimizeRx” and “the Company.” All material intercompany transactions have been eliminated.
Reclassifications	Reclassifications Certain items in the previous year financial statements have been reclassified to match the current year presentation.
Foreign Currency	Foreign Currency The Company’s functional currency is the U.S. dollar, however it pays certain expenses related to its two foreign subsidiaries in the local currency, which is the shekel for its subsidiary in Israel and the kuna for its Croatian subsidiary. All transactions are recorded at the exchange rate at the time of payment. If there is a time lag between the time of recording the liability and the time of payment, a gain or loss is recorded in the Consolidated Statement of Operations due to any fluctuations in the exchange rate.
Cash and Cash Equivalents	Cash and Cash Equivalents For purposes of the accompanying financial statements, the Company considers all highly liquid instruments, consisting of money market accounts, with an initial maturity of three months or less to be cash equivalents.
Investments	Investments We account for marketable securities in accordance with ASC 320, “Investments - Debt Securities”, which require that certain debt securities be classified into one of three categories: held-to-maturity, available-for-sale, or trading securities, and depending upon the classification, value the security at amortized cost or fair market value.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The fair value should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the fair value of liabilities should include consideration of non-performance risk including our own credit risk. In addition to defining fair value, the disclosure requirements around fair value establish a fair value hierarchy for valuation inputs, which is expanded. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels, which is determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are: Level 1 – Inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. Level 2 – Inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. The Company’s stock options and warrants are valued using level 3 inputs. The Company’s carrying amounts of financial instruments including cash and cash equivalents, accounts receivable, accounts payable, and other current liabilites approximate their fair values due to their short maturities.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are reported at realizable value, net of allowances for doubtful accounts, which is estimated and recorded in the period the related revenue is recorded. The Company has a standardized approach to estimate and review the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to allowances for doubtful accounts. In addition, the Company regularly assesses the state of its billing operations in order to identify issues, which may impact the collectability of these receivables or reserve estimates. Because the Company’s customers are primarily large well-capitalized companies, historically there has been very little bad debt expense. Bad debt expense was $363,512 for the year ended December 31, 2022 and $80,000 for the year ended December 31, 2021. The allowance for doubtful accounts was $352,043 and $241,219 as of December 31, 2022 and 2021, respectively. From time to time, we may record revenue based on our revenue recognition policies described below in advance of being able to invoice the customer. Included in accounts receivable are unbilled amounts of $3,582,735,$2,110,865 and $757,218 at December 31, 2022, 2021 and 2020, respectively.
Property and Equipment	Property and Equipment Property and equipment are stated at cost and are being depreciated over their estimated useful lives of three to five years for office equipment and three years for computer equipment using the straight-line method of depreciation for book purposes. Maintenance and repair charges are expensed as incurred.
Intangible Assets	Intangible Assets Intangible assets are stated at cost. Finite-lived assets are being amortized over their estimated useful lives of fifteen to seventeen years for patents, eight years for customer relationships, fifteen years for tradenames, two to four years for covenants not to compete, and three to ten years for software and websites, all using the straight-line method. These assets are evaluated when there is a triggering event. There was no impairment of our intangible assets in either year presented.
Goodwill	Goodwill We evaluate goodwill for impairment during our fiscal fourth quarter, or more frequently if an event occurs or circumstances change. Our analysis determined that there was no impairment of our goodwill.
Revenue Recognition	Revenue Recognition Recognition of revenue requires evidence of a contract, probable collection of proceeds, and completion of substantially all performance obligations. We use a 5-step model to recognize revenue. These steps are: identify the contract with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize revenue when or as the performance obligations are satisfied. Revenues are primarily generated from content delivery activities in which the Company delivers financial, clinical, or brand messaging through a distribution network of eprescribers and electronic health record technology providers (channel partners), directly to consumers, or from reselling services that complement the business. This content delivery for a customer is referred to as a program. Unless otherwise specified, revenue is recognized based on the selling price to customers. The Company’s contracts are generally all less than one year and the primary performance obligation is delivery of messages, or content, but the contract may contain additional services. Additional services may include program design, which is the design of the content delivery program, set up, and reporting. We consider set up and reporting services to be complimentary to the primary performance obligation and recognized through performance of the delivery of content. We consider program design and related consulting services to be performance obligations separate from the delivery of messages. As the content is distributed through the platform and network of channel partners (a transaction), these transactions are recorded, and revenue is recognized over time as the distributions occur. Revenue for transactions can be realized based on a price per message, a price per redemption, as a flat fee occurring over a period of time, or upon completion of the program, depending on the client contract. The Company recognizes setup fees that are required for integrating client offerings and campaigns into the rule-based content delivery system and network over the life of the initial program, based either on time, or units delivered, depending upon which is most appropriate in the specific situation. Should a program be cancelled before completion, the balance of set up revenue is recognized at the time of cancellation, as set up fees are nonrefundable. Additionally, the Company also recognizes revenue for providing program performance reporting and maintenance, either by the Company directly delivering reports or by providing access to its online reporting portal that the client can utilize. This reporting revenue is recognized over time as the messages are delivered. Program design, which is the design of the content delivery program, and related consulting services are recognized as services are performed. Disaggregation of Revenue Consistent with ASC Topic 606, we have disaggregated our revenue by timing of revenue recognition. The majority of our revenue is recognized over time as solutions are provided. A small portion of our revenue related to program development, solution architect design, and other solutions is recognized at a point in time upon delivery to customers. A break down is set forth in the table below. 2022 2021 Revenue recognized over time $ 55,437,418 $ 57,077,743 Revenue recognized at a point in time 7,012,738 4,214,855 Total Revenue $ 62,450,156 $ 61,292,598 Revenue Recognition (Continued) In some instances, we license certain of our software applications in arrangements that do not include other performance obligations. In those instances, we record license revenue when the software is delivered for use to the license. In instances where our contracts included Software as a Service, the revenue is recognized over the subscription period as services are delivered to the customer. In some instances, the Company also resells messaging solutions that are available through channel partners that are complementary to the core business and client base. These partner specific solutions are frequently similar to our own solutions and revenue recognition for these programs is the same as described above. In instances where the Company sells solutions on a commission basis, net revenue is recognized based on the commission-based revenue split that the Company receives. There were no programs recorded on a net basis in the years presented. In instances where the Company resells these messaging solutions and has all financial risk and significant operation input and risk, the Company records the revenue based on the gross amount sold and the amount paid to the channel partner as a cost of sales.
Cost of Revenues	Cost of Revenues The primary cost of revenue is revenue share expense. Cost of revenues does not include depreciation and amortization which is listed separately on the statements of operations. Based on the volume of transactions that are delivered through the channel partner network, the Company provides a revenue share to compensate the partner, or others, for their promotion of the campaign. Revenue shares are a negotiated percentage of the transaction fees and can also be specific to special considerations and campaigns.
Income Taxes	Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. The Company recognizes the tax benefit from uncertain tax positions if it is more likely than not that the tax positions will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefit is measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. It is the Company’s policy to include interest and penalties related to tax positions as a component of income tax expense.
Concentration of Credit Risks	Concentration of Credit Risks The Company maintains its cash and cash equivalents in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts; however, amounts in excess of the federally insured limit may be at risk if the bank experiences financial difficulties. As of December 31, 2022 and 2021 the Company had $15,669,837 and $83,312,524, respectively, in cash balances in excess of federally insured limits, primarily at Bank of America.
Research and Development	Research and Development The Company expenses research and development expenses as incurred. There was no research and development expense for the years ended December 31, 2022 and 2021.
Stock-based Compensation	Stock-based Compensation The Company uses the fair value method to account for stock-based compensation. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital over the period during which services are rendered. The fair value of each award is estimated on the date of each grant. For restricted stock awards, the fair value is based on the market value of the Company’s common stock on the date of grant. For market based restricted stock units, the fair value is estimated using a Monte Carlo simulation model. This valuation technique includes estimating the movement of stock prices and the effects of volatility, interest rates and dividends. For options, fair value is estimated using the Black-Scholes option pricing model that uses the following assumptions. Estimated volatilities are based on the historical volatility of the Company’s common stock over the same period as the expected term of the options. The expected term of options granted represents the period of time that options granted are expected to be outstanding. The Company uses historical data to estimate option exercise behavior and to determine this term. The risk-free rate used is based on the U.S. Treasury yield curve in effect at the time of the grant using a time period equal to the expected option term. The Company has never paid dividends and do not expect to pay any dividends in the future. 2022 2021 Expected dividend yield 0 % 0 % Risk free interest rate 0.82% - 4.38% 0.19% - 0.67% Expected option term 3.5 years 3.5 years Turnover/forfeiture rate 0 % 0 % Expected volatility 68% - 71% 67% - 70% Weighted average grant date fair value $ 12.82 $ 26.36 The Black-Scholes option valuation model and other existing models were developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. These option valuation models require the input of, and are highly sensitive to, subjective assumptions including the expected stock price volatility. The Company’s stock options have characteristics significantly different from those of traded options, and changes in the subjective input assumptions could materially affect the fair value estimate.
Loss Per Common and Common Equivalent Share	Loss Per Common and Common Equivalent Share The computation of basic (loss) earnings per common share is computed using the weighted average number of common shares outstanding during the year. The computation of diluted (loss) earnings per common share is based on the basic weighted average number of shares outstanding during the year plus common stock equivalents, which would arise from the exercise of options and warrants outstanding using the treasury stock method and the average market price per share during the year. The number of common shares potentially issuable upon the exercise of certain awards that were excluded from the diluted loss per common share calculation in 2022 was 93,626 related to options, and 170,859 related to restricted stock units, for a total of 264,485 because they are anti-dilutive, as a result of a net loss for the year ended December 31, 2022. The computation of weighted average shares outstanding and the basic and diluted earnings per common share for the years ended December 31, 2022 and 2021 consisted of the following: Year ended December 31, 2022 Net (Loss) Shares Per Share Basic EPS $ (11,438,440 ) 17,783,992 $ (0.64 ) Effect of dilutive securities — — — Diluted EPS $ (11,438,440 ) 17,783,992 $ (0.64 ) Year ended December 31, 2021 Net Income Shares Per Share Basic EPS $ 378,079 17,228,019 $ 0.02 Effect of dilutive securities 462,470 — Diluted EPS $ 378,079 17,690,489 $ 0.02
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company continually monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell.
Segment reporting	Segment reporting We operate in one reportable segment. Overall, our business involves connecting life science companies to patients and providers. We have a common customer base for all of our solutions, which are primarily all communications with healthcare providers or patients on behalf of life science customers. Our customers are geographically located in the U.S although we have two technology centers located internationally. We do not prepare separate internal income statements by solutions as our focus is on selling enterprise arrangements covering multiple solutions that span the entire patient journey with a specific brand.
Recently Issued Accounting Guidance	Recently Issued Accounting Guidance In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes
Not Yet Adopted	Not Yet Adopted ASU Topic 2021-08 Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Summary of Significant Accounting Policies [Abstract]
Schedule of revenue is earned from life sciences companies	2022 2021 Revenue recognized over time $ 55,437,418 $ 57,077,743 Revenue recognized at a point in time 7,012,738 4,214,855 Total Revenue $ 62,450,156 $ 61,292,598
Schedule of pay any dividends in the future	2022 2021 Expected dividend yield 0 % 0 % Risk free interest rate 0.82% - 4.38% 0.19% - 0.67% Expected option term 3.5 years 3.5 years Turnover/forfeiture rate 0 % 0 % Expected volatility 68% - 71% 67% - 70% Weighted average grant date fair value $ 12.82 $ 26.36
Schedule of weighted average shares outstanding and the basic and diluted earnings per common share	Year ended December 31, 2022 Net (Loss) Shares Per Share Basic EPS $ (11,438,440 ) 17,783,992 $ (0.64 ) Effect of dilutive securities — — — Diluted EPS $ (11,438,440 ) 17,783,992 $ (0.64 ) Year ended December 31, 2021 Net Income Shares Per Share Basic EPS $ 378,079 17,228,019 $ 0.02 Effect of dilutive securities 462,470 — Diluted EPS $ 378,079 17,690,489 $ 0.02

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	12 Months Ended
	Dec. 31, 2022
Prepaid Expenses [Abstract]
Schedule of prepaid expenses	2022 2021 Revenue share and exclusivity payments $ 1,025,000 $ 4,516,668 Software 408,063 181,044 Insurance 221,580 156,327 Data 152,533 168,462 Other 473,652 608,154 Total prepaid expenses $ 2,280,828 $ 5,630,655

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of owned equipment recorded at cost	2022 2021 Computer equipment $ 230,467 $ 267,917 Furniture and fixtures 38,500 200,250 268,967 468,167 Less accumulated depreciation 131,519 324,349 Property and equipment, net $ 137,448 $ 143,818

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of goodwill on the consolidated balance sheet	Balance at January 1, 2021 $ 14,740,031 Acquisitions - Impairments - Balance January 1, 2022 $ 14,740,031 Revenue recognized 7,933,789 Amount collected - Balance December 31, 2022 $ 22,673,820
Schedule of intangible assets included on the consolidated balance sheets	December 31, 2022 Gross Accumulated Net Weighted Patent rights $ 3,364,729 $ 1,424,551 $ 1,940,178 8.5 Technology assets 12,859,660 5,156,765 7,702,895 5.1 Other intangible assets Tradename 3,586,000 776,966 2,809,034 11.7 Non-compete agreements 1,093,000 1,093,000 — 0 Customer relationships 923,000 352,196 570,804 7.4 Total other 5,602,000 2,222,162 3,379,838 Total intangible assets $ 21,826,389 $ 8,803,478 $ 13,022,911 December 31, 2021 Gross Accumulated Net Weighted Patent rights $ 3,362,898 $ 1,207,872 $ 2,155,026 9.6 Technology assets 8,548,930 3,959,804 4,589,126 4.9 Other intangible assets Tradename 3,586,000 537,900 3,048,100 12.7 Non-compete agreements 1,093,000 899,635 193,365 0.6 Customer relationships 923,000 261,963 661,037 8.4 Total other 5,602,000 1,699,498 3,902,502 Total intangible assets $ 17,513,828 $ 6,867,174 $ 10,646,654
Schedule of intangibles are being amortized on a straight-line basis	Patents 15 – 17 years Tradenames 15 years Non-compete agreements 2 – 4 years Customer relationships 8 years Technology assets 3 – 10 years
Schedule of future amortization expenses of intangibles assets	Year ended December 31, 2023 $ 1,769,212 2024 1,769,212 2025 1,682,054 2026 1,566,184 2027 1,483,765 Thereafter 4,752,484 Total $ 13,022,911

Deferred Revenue (Tables)

Deferred Revenue (Tables)	12 Months Ended
	Dec. 31, 2022
Revenues [Abstract]
Schedule of deferred revenue	Balance January 1, 2022 $ 1,389,907 Revenue recognized (36,346,653 ) Amount collected 35,121,055 Balance December 31, 2022 $ 164,309 Balance January 1, 2021 $ 285,795 Revenue recognized (18,006,973 ) Amount collected 19,111,085 Balance December 31, 2021 $ 1,389,907

Stock Based Compensation (Table

Stock Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2022
Stock Based Compensation [Abstract]
Schedule of restricted stock awards	Number of Options Weighted average exercise price Weighted average remaining contractual life (years) Aggregate intrinsic Outstanding at January 1, 2021 1,545,518 $ 7.31 Granted 424,588 $ 54.34 Exercised (1,105,822 ) $ 7.33 Withheld and cancelled (31,243 ) 3.21 Expired or forfeited (49,494 ) $ 24.57 Outstanding at December 31, 2021 783,547 $ 34.17 3.4 $ 23,368,961 Granted 862,938 $ 25.43 Exercised (156,910 ) $ 7.69 Expired or forfeited (182,705 ) $ 37.13 Outstanding, December 31, 2022 1,306,870 $ 31.14 2.7 $ 1,537,752 Exercisable, December 31, 2022 250,684 $ 33.82 2.6 $ 538,652
Schedule of total options outstanding	Range of Exercise Prices Number of Options Weighted average remaining contractual life (years) Weighted average exercise price $4.20 to $10.00 30,335 1.5 $ 6.40 $10.00 to $20.00 568,358 2.6 $ 14.66 $20.00 to $40.00 322,916 2.6 $ 33.79 $40.00 to $60.00 284,231 2.8 $ 47.99 $60.00 to $96.70 101,030 3.7 $ 75.43 Total 1,306,870 2.7 $ 31.14 Range of Exercise Prices Number of Options Weighted average remaining contractual life (years) Weighted average exercise price $4.20 to $10.00 24,168 1.3 $ 6.22 $10.00 to $20.00 69,868 1.7 $ 12.84 $20.00 to $40.00 69,170 2.9 $ 30.77 $40.00 to $60.00 54,667 3.3 $ 51.54 $60.00 to$96.70 32,811 3.7 $ 75.74 Total 250,684 2.6 $ 33.82
Schedule of nonvested shares	Nonvested Options Options Weighted average exercise price Nonvested at January 1, 2022 586,276 $ 42.01 Granted 862,938 $ 25.43 Vested (223,323 ) $ 35.04 Forfeited (169,705 ) $ 37.83 Nonvested at December 31, 2022 1,056,186 $ 30.51
Schedule of restricted stock unit	Number of RSUs Weighted average grant date fair value Weighted average remaining contractual life (years) Outstanding at January 1, 2021 100,000 $ 11.51 Granted 303,556 $ 66.30 Forfeited (485 ) $ 61.82 Shares issued (3,333 ) $ 21.20 Outstanding at December 31, 2021 399,738 $ 52.99 3.3 Granted 467,043 $ 25.69 Forfeited (39,346 ) $ 44.06 Vested and issued (29,945 ) $ 59.41 Withheld and cancelled (8,416 ) $ 68.69 Outstanding at December 31, 2022 789,074 $ 36.95 2.0

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Schedule of lease cost	2022 2021 Operating lease cost $ 100,771 $ 132,305 Short-term lease cost (1) 75,784 52,375 Total lease cost $ 176,555 $ 184,680 (1) Short-term lease cost includes any lease with a term of less than 12 months.
Schedule of future minimum lease payments	For the year ending December 31, 2023 $ 98,247 2024 80,215 2025 70,224 Total 248,686 Less: present value discount 14,252 Total lease liabilities $ 234,434

Major Customers and Vendors (Ta

Major Customers and Vendors (Tables)	12 Months Ended
	Dec. 31, 2022
Risks and Uncertainties [Abstract]
Schedule of customers accounted percentage of revenue	2022 2021 $ % $ % Customer A 6,817,682 10.9 5,206,305 8.5 Customer B 3,876,580 6.2 14,268,819 23.0 2022 2021 $ % $ % Partner A 19,882,511 31.8 33,041,503 53.9 Partner B 12,494,227 20.0 2,761,893 4.5 Partner C 6,578,661 10.5 9,554,266 15.6

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of federal income tax benefit	2022 2021 Federal income tax benefit (expense) attributable to: Current operations $ 2,402,000 $ (79,000 ) State tax effect, net of federal benefit 545,000 979,000 Option exercise benefits (expenses), net of Section 162M limitations (268,000 ) 2,171,000 Other adjustments 221,000 (30,000 ) NOLs expiring — (26,000 ) Valuation allowance (2,900,000 ) (3,006,000 ) Net provision for federal income tax $ — $ — 2022 2021 Current tax benefit (expense) - Federal $ — $ — Deferred tax benefit (expense) - Federal — — Adjustment of valuation allowance from business combination — — Total tax benefit (expense) on income $ — $ —
Schedule of deferred tax assets	2022 2021 Deferred tax asset attributable to: Net operating loss carryover $ 5,545,000 $ 6,887,000 Stock compensation 3,953,000 809,000 Operating lease liability 63,000 88,000 Section 174 Capitalized Expenses 789,000 — Fixed Assets 126,000 13,000 Other 16,000 85,000 Deferred tax asset $ 10, 492,000 $ 7,882,000 Deferred tax liabilities attributable to: Intangibles $ (2,102,000 ) $ (2,490,000 ) Operating lease right of use assets (63,000 ) (88,000 ) Goodwill (106,000 ) — Other (59,000 ) (42,000 ) Deferred tax liability (2,330,000 ) (2,620,000 ) Net deferred tax asset $ 8,162,000 $ 5,262,000 Valuation allowance (8,162,000 ) (5,262,000 ) Net deferred tax asset, net of valuation allowance $ — $ —

Organization and Nature of Bu_2

Organization and Nature of Business (Details)	12 Months Ended
	Dec. 31, 2022
Organization and Nature of Business [Abstract]
U.S. healthcare providers percentage	60%

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Summary of Significant Accounting Policies (Details) [Line Items]
Bad debt expense	$ 363,512	$ 80,000
Allowance for doubtful accounts	352,043	241,219
Unbilled amounts of accounts receivable	$ 3,582,735	2,110,865	$ 757,218
Percentage of realized upon ultimate settlement	50%
Cash balances for insured limits	$ 15,669,837	$ 83,312,524
Diluted loss per common share (in Shares)	93,626
Restricted stock (in Shares)	170,859
Restricted Stock [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Restricted stock (in Shares)	264,485

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of revenue is earned from life sciences companies - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Revenue Is Earned From Life Sciences Companies Abstract
Revenue recognized over time	$ 55,437,418	$ 57,077,743
Revenue recognized at a point in time	7,012,738	4,214,855
Total Revenue	$ 62,450,156	$ 61,292,598

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details) - Schedule of pay any dividends in the future - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected dividend yield	0%	0%
Expected option term	3 years 6 months	3 years 6 months
Turnover/forfeiture rate	0%	0%
Weighted average grant date fair value (in Dollars)	$ 12.82	$ 26.36
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk free interest rate	0.82%	0.19%
Expected volatility	68%	67%
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk free interest rate	4.38%	0.67%
Expected volatility	71%	70%

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details) - Schedule of weighted average shares outstanding and the basic and diluted earnings per common share - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Weighted Average Shares Outstanding And The Basic And Diluted Earnings Per Common Share Abstract
Basic EPS, Net (Loss)	$ (11,438,440)	$ 378,079
Basic EPS, Shares	17,783,992	17,228,019
Basic EPS, Per Share Amount	$ (0.64)	$ 0.02
Effect of dilutive securities, Net (Loss)
Effect of dilutive securities, Shares		462,470
Effect of dilutive securities, Per Share Amount
Diluted EPS, Net (Loss)	$ (11,438,440)	$ 378,079
Diluted EPS, Shares	17,783,992	17,690,489
Diluted EPS, Per Share Amount	$ (0.64)	$ 0.02

Acquisitions (Details)

Acquisitions (Details)	Apr. 14, 2022 USD ($) shares
Acquisitions (Details) [Line Items]
Issuance of shares of common stock (in Shares) | shares	240,741
Common stock value	$ 9,374,455
Purchase price	$ 12,082,789
Total shares issued (in Shares) | shares	185,185
Estimated useful life	8 years
Goodwill	$ 7,933,789
Acquisition costs	19,739
Acquisitions [Member]
Acquisitions (Details) [Line Items]
Cash	2,000,000
Previously paid amount	708,334
Purchase price	$ 4,149,000
EvinceMed [Member]
Acquisitions (Details) [Line Items]
Issuance of shares of common stock (in Shares) | shares	240,741
Shares issued (in Shares) | shares	55,556

Investment Securities (Details)

Investment Securities (Details) $ in Millions	Dec. 31, 2022 USD ($)
Investment Securities [Abstract]
U.S. government and agency securities	$ 55.9

Prepaid Expenses (Details) - Sc

Prepaid Expenses (Details) - Schedule of prepaid expenses - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule of prepaid expenses [Abstract]
Revenue share and exclusivity payments	$ 1,025,000	$ 4,516,668
Software	408,063	181,044
Insurance	221,580	156,327
Data	152,533	168,462
Other	473,652	608,154
Total prepaid expenses	$ 2,280,828	$ 5,630,655

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 85,725	$ 105,360

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of owned equipment recorded at cost - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property plant and equipment	$ 268,967	$ 468,167
Less accumulated depreciation	131,519	324,349
Property and equipment, net	137,448	143,818
Computer equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment	230,467	267,917
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment	$ 38,500	$ 200,250

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Company recorded amortization expense	$ 1,936,304	$ 1,859,965

Intangible Assets (Details) - S

Intangible Assets (Details) - Schedule of goodwill on the consolidated balance sheet - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Goodwill On The Consolidated Balance Sheet Abstract
Balance	$ 14,740,031	$ 14,740,031
Revenue recognized	7,933,789
Amount collected
Balance	$ 22,673,820	14,740,031
Acquisitions
Impairments

Intangible Assets (Details) -_2

Intangible Assets (Details) - Schedule of intangible assets included on the consolidated balance sheets - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Gross Carrying Amount	$ 21,826,389	$ 17,513,828
Accumulated Amortization	8,803,478	6,867,174
Intangible assets, Net	13,022,911	10,646,654
Patent rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Gross Carrying Amount	3,364,729	3,362,898
Accumulated Amortization	1,424,551	1,207,872
Intangible assets, Net	$ 1,940,178	$ 2,155,026
Weighted Average Life Remaining	8 years 6 months	9 years 7 months 6 days
Technology Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Gross Carrying Amount	$ 12,859,660	$ 8,548,930
Accumulated Amortization	5,156,765	3,959,804
Intangible assets, Net	$ 7,702,895	$ 4,589,126
Weighted Average Life Remaining	5 years 1 month 6 days	4 years 10 months 24 days
Tradename [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Gross Carrying Amount	$ 3,586,000	$ 3,586,000
Accumulated Amortization	776,966	537,900
Intangible assets, Net	$ 2,809,034	$ 3,048,100
Weighted Average Life Remaining	11 years 8 months 12 days	12 years 8 months 12 days
Non-compete agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Gross Carrying Amount	$ 1,093,000	$ 1,093,000
Accumulated Amortization	1,093,000	899,635
Intangible assets, Net		$ 193,365
Weighted Average Life Remaining	0 years	7 months 6 days
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Gross Carrying Amount	$ 923,000	$ 923,000
Accumulated Amortization	352,196	261,963
Intangible assets, Net	$ 570,804	$ 661,037
Weighted Average Life Remaining	7 years 4 months 24 days	8 years 4 months 24 days
Total other [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, Gross Carrying Amount	$ 5,602,000	$ 5,602,000
Accumulated Amortization	2,222,162	1,699,498
Intangible assets, Net	$ 3,379,838	$ 3,902,502

Intangible Assets (Details) -_3

Intangible Assets (Details) - Schedule of intangibles are being amortized on a straight-line basis	12 Months Ended
	Dec. 31, 2022
Patents [Member] | Minimum [Member]
Intangible Assets (Details) - Schedule of intangibles are being amortized on a straight-line basis [Line Items]
Intangibles amortized estimated useful lives	15 years
Patents [Member] | Maximum [Member]
Intangible Assets (Details) - Schedule of intangibles are being amortized on a straight-line basis [Line Items]
Intangibles amortized estimated useful lives	17 years
Tradenames [Member]
Intangible Assets (Details) - Schedule of intangibles are being amortized on a straight-line basis [Line Items]
Intangibles amortized estimated useful lives	15 years
Non-compete agreements [Member] | Minimum [Member]
Intangible Assets (Details) - Schedule of intangibles are being amortized on a straight-line basis [Line Items]
Intangibles amortized estimated useful lives	2 years
Non-compete agreements [Member] | Maximum [Member]
Intangible Assets (Details) - Schedule of intangibles are being amortized on a straight-line basis [Line Items]
Intangibles amortized estimated useful lives	4 years
Customer relationships [Member]
Intangible Assets (Details) - Schedule of intangibles are being amortized on a straight-line basis [Line Items]
Intangibles amortized estimated useful lives	8 years
Technology assets [Member] | Minimum [Member]
Intangible Assets (Details) - Schedule of intangibles are being amortized on a straight-line basis [Line Items]
Intangibles amortized estimated useful lives	3 years
Technology assets [Member] | Maximum [Member]
Intangible Assets (Details) - Schedule of intangibles are being amortized on a straight-line basis [Line Items]
Intangibles amortized estimated useful lives	10 years

Intangible Assets (Details) -_4

Intangible Assets (Details) - Schedule of future amortization expenses of intangibles assets	Dec. 31, 2022 USD ($)
Schedule Of Future Amortization Expenses Of Intangibles Assets Abstract
2023	$ 1,769,212
2024	1,769,212
2025	1,682,054
2026	1,566,184
2027	1,483,765
Thereafter	4,752,484
Total	$ 13,022,911

Deferred Revenue (Details)

Deferred Revenue (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Revenues [Abstract]
Deferred revenue	$ 164,309	$ 1,389,907

Deferred Revenue (Details) - Sc

Deferred Revenue (Details) - Schedule of deferred revenue - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Deferred Revenue Abstract
Balance	$ 1,389,907	$ 285,795
Revenue recognized	(36,346,653)	(18,006,973)
Amount collected	35,121,055	19,111,085
Balance	$ 164,309	$ 1,389,907

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2010
Related Party Transactions [Abstract]
Total payment in shares of common stock and options value			$ 930,000
Revenue amount	$ 401,972	$ 218,333

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Stockholders' Equity (Details) [Line Items]
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	166,666,667	166,666,667
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares issued	18,288,571	17,860,975
Shares of common stock issued	156,910	1,105,822
Received proceeds (in Dollars)	$ 1,205,881	$ 4,864,231
Shares of common stock issued		1,523,750
Gross proceeds (in Dollars)		$ 75,425,625
Issuance of common stock exercise value (in Dollars)		4,754,089
Payments to advisors and legal fees (in Dollars)		$ 70,671,536
Repurchased shares	1,214,398
Commissions paid (in Dollars)	$ 20,024,258
Preferred Stock [Member]
Stockholders' Equity (Details) [Line Items]
Preferred stock, shares authorized	10,000,000
Preferred stock, par value (in Dollars per share)	$ 0.001
Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Common stock, shares issued	17,074,173	17,860,975
Shares of common stock issued	29,945	3,333
Outstanding common stock (in Dollars)	$ 20,000,000
Director [Member]
Stockholders' Equity (Details) [Line Items]
Shares of common stock issued		4,730
Gross proceeds (in Dollars)		$ 250,085

Stock Based Compensation (Detai

Stock Based Compensation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Stock Based Compensation (Details) [Line Items]
Authorized shares	3,000,000
Shares of common stock options	410,701
Shares of common stock (in Dollars per share)	$ 128,590
Shares are authorized issuance		2,500,000
Common stock options	896,169
Common stock underlying restricted stock unit	660,484
Grant shares	921,946
Fair market value rate	100%
Options exercised value (in Dollars)		$ 100,290
Expense remaining to be recognized related to unvested options (in Dollars)	$ 12,528,706
Expense remaining over a period	2 years 1 month 6 days
Granted restricted stock description	The Company granted restricted stock units of 467,043 and 303,556 units in 2022 and 2021, respectively, and valued at $11,996,111 and $20,125,861, respectively. These restricted stock units vest over a period of 1 year to 5 years. The Company recognized expense of $10,789,203 and $2,532,091 in 2022 and 2021, respectively, related to these restricted stock units.
Restricted stock granted remains value (in Dollars)	$ 17,862,951
Remains to be recognized over period	2 years
Cumulative net shares issued surrendered	31,243
Cumulative net shares issued cancelled	100,290
Restricted stock unit description		Of the restricted stock units issued in 2021, 182,938 are market-based awards that vest if the Company’s stock price hits certain price targets and maintains that price for 30 days. A total of 60,191, 60,191, and 62,016 units vest if the stock price hits $98.87, $131.82, and $164.78, respectively. As described in Note 2, these market-based restricted stock units were valued using a Monte Carlo simulation model, with expected vesting in 1.60, 2.25, and 2.71 years, respectively, for the three price targets. During the year ended December 31, 2022, we granted certain performance based stock units, the expense for which will be recorded over time once the achievement of the performance is deemed probable.
Shares issued	4,730
Shares valued (in Dollars)	$ 250,085
Granted units	3,715
Restricted stock units	26,470
Total value of vest (in Dollars)	$ 750,130
Vest from the grant date	12 months
Minimum [Member]
Stock Based Compensation (Details) [Line Items]
Options exercised shares		31,243
Equity Compensation Plan [Member]
Stock Based Compensation (Details) [Line Items]
Stock compensation recognized expense (in Dollars)	$ 4,956,619	$ 2,709,781
Non-employee directors’ compensation [Member]
Stock Based Compensation (Details) [Line Items]
Shares of common stock (in Dollars per share)	$ 250,175

Stock Based Compensation (Det_2

Stock Based Compensation (Details) - Schedule of restricted stock awards - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Restricted Stock Awards Abstract
Outstanding at Number of Options	783,547	1,545,518
Outstanding at Number of Options	$ 34.17	$ 7.31
Number of Options, Granted	862,938	424,588
Weighted average exercise price, Granted	$ 25.43	$ 54.34
Number of Options, Exercised	(156,910)	(1,105,822)
Weighted average exercise price, Exercised	$ 7.69	$ 7.33
Number of Options, Withheld and cancelled		(31,243)
Weighted average exercise price, Withheld and cancelled		$ 3.21
Number of Options, Expired or forfeited	(182,705)	(49,494)
Weighted average exercise price, Expired or forfeited	$ 37.13	$ 24.57
Number of Options, Outstanding	1,306,870	783,547
Weighted average exercise price, Outstanding	$ 31.14	$ 34.17
Weighted average remaining contractual life (years), Outstanding	2 years 8 months 12 days	3 years 4 months 24 days
Aggregate intrinsic value, Outstanding	$ 1,537,752	$ 23,368,961
Number of Options, Exercisable	250,684
Weighted average exercise price, Exercisable	$ 33.82
Weighted average remaining contractual life (years), Exercisable	2 years 7 months 6 days
Aggregate intrinsic value, Exercisable	$ 538,652

Stock Based Compensation (Det_3

Stock Based Compensation (Details) - Schedule of total options outstanding	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Total Option Outstanding [Member] | Exercise Price Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options (in Shares) | shares	30,335
Weighted average remaining contractual life (years)	1 year 6 months
Weighted average exercise price	$ 6.4
Total Option Outstanding [Member] | Exercise Price Range One [Member] | Minimum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	4.2
Total Option Outstanding [Member] | Exercise Price Range One [Member] | Maximum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	$ 10
Total Option Outstanding [Member] | Exercise Price Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options (in Shares) | shares	568,358
Weighted average remaining contractual life (years)	2 years 7 months 6 days
Weighted average exercise price	$ 14.66
Total Option Outstanding [Member] | Exercise Price Range Two [Member] | Minimum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	10
Total Option Outstanding [Member] | Exercise Price Range Two [Member] | Maximum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	$ 20
Total Option Outstanding [Member] | Exercise Price Range Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options (in Shares) | shares	322,916
Weighted average remaining contractual life (years)	2 years 7 months 6 days
Weighted average exercise price	$ 33.79
Total Option Outstanding [Member] | Exercise Price Range Three [Member] | Minimum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	20
Total Option Outstanding [Member] | Exercise Price Range Three [Member] | Maximum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	$ 40
Total Option Outstanding [Member] | Exercise Price Range Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options (in Shares) | shares	284,231
Weighted average remaining contractual life (years)	2 years 9 months 18 days
Weighted average exercise price	$ 47.99
Total Option Outstanding [Member] | Exercise Price Range Four [Member] | Minimum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	40
Total Option Outstanding [Member] | Exercise Price Range Four [Member] | Maximum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	$ 60
Total Option Outstanding [Member] | Exercise Price Range Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options (in Shares) | shares	101,030
Weighted average remaining contractual life (years)	3 years 8 months 12 days
Weighted average exercise price	$ 75.43
Total Option Outstanding [Member] | Exercise Price Range Five [Member] | Minimum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	60
Total Option Outstanding [Member] | Exercise Price Range Five [Member] | Maximum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	$ 96.7
Total Option Outstanding [Member] | Exercise Price Range [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options (in Shares) | shares	1,306,870
Weighted average remaining contractual life (years)	2 years 8 months 12 days
Weighted average exercise price	$ 31.14
Vested Options Outstanding [Member] | Exercise Price Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options (in Shares) | shares	24,168
Weighted average remaining contractual life (years)	1 year 3 months 18 days
Weighted average exercise price	$ 6.22
Vested Options Outstanding [Member] | Exercise Price Range One [Member] | Minimum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	4.2
Vested Options Outstanding [Member] | Exercise Price Range One [Member] | Maximum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	$ 10
Vested Options Outstanding [Member] | Exercise Price Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options (in Shares) | shares	69,868
Weighted average remaining contractual life (years)	1 year 8 months 12 days
Weighted average exercise price	$ 12.84
Vested Options Outstanding [Member] | Exercise Price Range Two [Member] | Minimum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	10
Vested Options Outstanding [Member] | Exercise Price Range Two [Member] | Maximum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	$ 20
Vested Options Outstanding [Member] | Exercise Price Range Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options (in Shares) | shares	69,170
Weighted average remaining contractual life (years)	2 years 10 months 24 days
Weighted average exercise price	$ 30.77
Vested Options Outstanding [Member] | Exercise Price Range Three [Member] | Minimum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	20
Vested Options Outstanding [Member] | Exercise Price Range Three [Member] | Maximum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	$ 40
Vested Options Outstanding [Member] | Exercise Price Range Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options (in Shares) | shares	54,667
Weighted average remaining contractual life (years)	3 years 3 months 18 days
Weighted average exercise price	$ 51.54
Vested Options Outstanding [Member] | Exercise Price Range Four [Member] | Minimum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	40
Vested Options Outstanding [Member] | Exercise Price Range Four [Member] | Maximum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	$ 60
Vested Options Outstanding [Member] | Exercise Price Range Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options (in Shares) | shares	32,811
Weighted average remaining contractual life (years)	3 years 8 months 12 days
Weighted average exercise price	$ 75.74
Vested Options Outstanding [Member] | Exercise Price Range Five [Member] | Minimum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	60
Vested Options Outstanding [Member] | Exercise Price Range Five [Member] | Maximum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	$ 96.7
Vested Options Outstanding [Member] | Exercise Price Range [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options (in Shares) | shares	250,684
Weighted average remaining contractual life (years)	2 years 7 months 6 days
Weighted average exercise price	$ 33.82

Stock Based Compensation (Det_4

Stock Based Compensation (Details) - Schedule of nonvested shares	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Schedule Of Nonvested Shares Abstract
Options, Nonvested at beginning balance | shares	586,276
Weighted-Average Exercise Price, Nonvested at beginning balance | $ / shares	$ 42.01
Options, Granted | shares	862,938
Weighted-Average Exercise Price, Granted | $ / shares	$ 25.43
Options, Vested | shares	(223,323)
Weighted-Average Exercise Price, Vested | $ / shares	$ 35.04
Options, Forfeited | shares	(169,705)
Weighted-Average Exercise Price, Forfeited | $ / shares	$ 37.83
Options, Nonvested at ending balance | shares	1,056,186
Weighted-Average Exercise Price, Nonvested at ending balance | $ / shares	$ 30.51

Stock Based Compensation (Det_5

Stock Based Compensation (Details) - Schedule of restricted stock unit - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Restricted Stock Unit Abstract
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	399,738	100,000
Weighted grant date fair value Outstanding, beginning		$ 11.51
Number of RSUs, Granted	467,043	303,556
Weighted grant date fair value, Granted	$ 25.69	$ 66.3
Number of RSUs, Forfeited	(39,346)	(485)
Weighted grant date fair value, Forfeited	$ 44.06	$ 61.82
Number of RSUs, Vested and issued	(29,945)
Weighted grant date fair value, Vested and issued	$ 59.41
Number of RSUs, Withheld and cancelled	(8,416)
Weighted grant date fair value, Withheld and cancelled	$ 68.69
Number of RSUs, Shares issued		(3,333)
Weighted grant date fair value, Shares issued		$ 21.2
Number of RSUs Outstanding, ending	789,074	399,738
Weighted grant date fair value, Outstanding, ending	$ 36.95	$ 52.99
Weighted average remaining contractual life (years) Outstanding, ending	2 years	3 years 3 months 18 days

Leases (Details)

Leases (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Leases (Details) [Line Items]
Operating leases with terms	Nov. 30, 2023
Operating leases description	We have assumed renewal of the lease. We also had a lease on office space in Cranbury, New Jersey, which expired in January 2022 with a monthly payment of $3,158, as well as a lease of approximately $1,883 per month in Zagreb, Croatia expiring in 2024.
Weighted average remaining lease term	2 years 8 months 12 days
Weighted average discount rate	4.50%
Cash paid	$ 89,111
Payments on lease obligations	101,405	$ 142,284
Amortization on the right of use assets	101,433
Amortization on right of use assets		$ 121,129
Minimum [Member]
Leases (Details) [Line Items]
Operating leases rent payable	6,384
Maximum [Member]
Leases (Details) [Line Items]
Operating leases rent payable	$ 6,688

Leases (Details) - Schedule of

Leases (Details) - Schedule of lease cost - USD ($)		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021
Schedule Of Lease Cost Abstract
Operating lease cost		$ 100,771	$ 132,305
Short-term lease cost (1)	[1]	75,784	52,375
Total lease cost		$ 176,555	$ 184,680
[1] Short-term lease cost includes any lease with a term of less than 12 months.

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of future minimum lease payments	12 Months Ended
	Dec. 31, 2022 USD ($)
Schedule Of Future Minimum Lease Payments Abstract
2023	$ 98,247
2024	80,215
2025	70,224
Total	248,686
Less: present value discount	14,252
Total lease liabilities	$ 234,434

Major Customers and Vendors (De

Major Customers and Vendors (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Major Customers and Vendors (Details) [Line Items]
Concentration Risk Percentage	10%
Other Customer [Member]
Major Customers and Vendors (Details) [Line Items]
Concentration Risk Percentage	10%
Key Partners [Member]
Major Customers and Vendors (Details) [Line Items]
Concentration Risk Percentage	10%
Accounts Receivable [Member]
Major Customers and Vendors (Details) [Line Items]
Concentration Risk Percentage	10%	10%
Accounts Receivable [Member] | Two Entities [Member]
Major Customers and Vendors (Details) [Line Items]
Concentration Risk Percentage	13.30%
Accounts Receivable [Member] | Three Entities [Member]
Major Customers and Vendors (Details) [Line Items]
Concentration Risk Percentage	10.80%
Accounts Receivable [Member] | One Agencies [Member]
Major Customers and Vendors (Details) [Line Items]
Concentration Risk Percentage		33.50%
Accounts Receivable [Member] | Two Agencies [Member]
Major Customers and Vendors (Details) [Line Items]
Concentration Risk Percentage		12.20%

Major Customers and Vendors (_2

Major Customers and Vendors (Details) - Schedule of customers accounted percentage of revenue - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Customer A [Member]
Segment Reporting Information [Line Items]
Revenue	$ 6,817,682	$ 5,206,305
Revenue percentage	10.90%	8.50%
Customer B [Member]
Segment Reporting Information [Line Items]
Revenue	$ 3,876,580	$ 14,268,819
Revenue percentage	6.20%	23%
Partner A [Member]
Segment Reporting Information [Line Items]
Revenue	$ 19,882,511	$ 33,041,503
Revenue percentage	31.80%	53.90%
Partner B [Member]
Segment Reporting Information [Line Items]
Revenue	$ 12,494,227	$ 2,761,893
Revenue percentage	20%	4.50%
Partner C [Member]
Segment Reporting Information [Line Items]
Revenue	$ 6,578,661	$ 9,554,266
Revenue percentage	10.50%	15.60%

Income Taxes (Details)

Income Taxes (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Operating loss expire, description	As of December 31, 2022, the Company had net operating loss (“NOLs”) carry-forwards for federal income tax purposes of approximately $21.5 million, consisting of pre-2018 losses in the amount of approximately $8.2 million that expire from 2022 through 2037, and post-2017 losses in the amount of approximately $13.3 million that will never expire.
Effective rate of tax expected	21%	21%

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of federal income tax benefit - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Federal Income Tax Benefit Abstract
Current operations	$ 2,402,000	$ (79,000)
State tax effect, net of federal benefit	545,000	979,000
Option exercise benefits (expenses), net of Section 162M limitations	(268,000)	2,171,000
Other adjustments	221,000	(30,000)
NOLs expiring		(26,000)
Valuation allowance	(2,900,000)	(3,006,000)
Net provision for federal income tax
Current tax benefit (expense) - Federal
Deferred tax benefit (expense) - Federal
Adjustment of valuation allowance from business combination
Total tax benefit (expense) on income

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of deferred tax assets - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Deferred tax asset attributable to:
Net operating loss carryover	$ 5,545,000	$ 6,887,000
Stock compensation	3,953,000	809,000
Operating lease liability	63,000	88,000
Section 174 Capitalized Expenses	789,000
Fixed Assets	126,000	13,000
Other	16,000	85,000
Deferred tax asset	10,492,000	7,882,000
Intangibles	(2,102,000)	(2,490,000)
Operating lease right of use assets	(63,000)	(88,000)
Goodwill	(106,000)
Other	(59,000)	(42,000)
Deferred tax liability	(2,330,000)	(2,620,000)
Net deferred tax asset	8,162,000	5,262,000
Valuation allowance	(8,162,000)	(5,262,000)
Net deferred tax asset, net of valuation allowance

Commitments and Contingent Li_2

Commitments and Contingent Liabilities (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Commitments and Contingent Liabilities (Details) [Line Items]
Underpayment percentage				10%
Future minimum payments				$ 16.4
Forecast [Member]
Commitments and Contingent Liabilities (Details) [Line Items]
Minimum payments due	$ 5	$ 5.2	$ 6.2

Retirement Plan (Details)

Retirement Plan (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Retirement Benefits [Abstract]
Defined contribution plan, description	Under the terms of the plan, the Company matches 100% of the first 3% of payroll contributed by the employee and 50% of the next 2% of payroll contributed by the employee to a maximum of 4% of an employee’s payroll.
Contributions plan expense	$ 489,780	$ 343,221